NCT06946108

Brief Summary

Pancreatic exocrine insufficiency (PEI) is one of the common complications of chronic pancreatitis (CP). Mild to moderate PEI may present with atypical digestive tract symptoms such as abdominal distension and abdominal pain, while severe PEI can lead to related complications such as foul-smelling stools, steatorrhea, weight loss, and malnutrition. Currently, there is no relevant report on the status quo of PEI in Chinese CP patients. This study aims to analyze the status quo of PEI and related risk factors in Chinese CP patients, with the hope of providing safe and effective intervention and treatment methods to improve the quality of life of patients.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,101

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2022

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2022

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2024

Completed
10 days until next milestone

Study Completion

Last participant's last visit for all outcomes

October 10, 2024

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

April 7, 2025

Completed
20 days until next milestone

First Posted

Study publicly available on registry

April 27, 2025

Completed
Last Updated

April 27, 2025

Status Verified

April 1, 2025

Enrollment Period

2.3 years

First QC Date

April 7, 2025

Last Update Submit

April 23, 2025

Conditions

Keywords

chronic pancreatitisPancreatic Exocrine Insufficiency

Outcome Measures

Primary Outcomes (1)

  • Detection of Pancreatic Exocrine Function in CP Patients

    For CP patients who are hospitalized, they are recruited to voluntarily preserve their feces for the detection of fecal elastase-1 (FE-1) so as to evaluate the pancreatic exocrine function.

    Day 1

Secondary Outcomes (3)

  • The demographic information of the patients

    Day 1

  • The information of the patients' natural disease course

    Day 1

  • Relevant treatment information for chronic pancreatitis (CP)

    Day 1

Study Arms (1)

the patients diagnosed with chronic pancreatitis who underwent inpatient care

This hospital-based cohort study enrolled patients diagnosed with chronic pancreatitis (CP) who underwent inpatient care at Shanghai Changhai Hospital (a WHO Collaborating Center for Pancreatology) between June 2022 and September 2024,Voluntary retention of fecal samples for FE-1 detection in CP patients

Diagnostic Test: Detection of Pancreatic Exocrine Function in Patients with Chronic Pancreatitis (CP)

Interventions

For CP patients who are hospitalized, they are recruited to voluntarily preserve their feces for the detection of fecal elastase-1 (FE-1) so as to evaluate the pancreatic exocrine function.

the patients diagnosed with chronic pancreatitis who underwent inpatient care

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

This hospital-based cohort study enrolled patients diagnosed with chronic pancreatitis (CP) who underwent inpatient care at Shanghai Changhai Hospital (a WHO Collaborating Center for Pancreatology) between June 2022 and September 2024

You may qualify if:

  • patients who underwent inpatient care at Shanghai Changhai Hospital (a WHO Collaborating Center for Pancreatology) between June 2022 and September 2024.
  • patients diagnosed with chronic pancreatitis (CP)
  • Voluntarily preserve feces for the detection of fecal elastase-1 (FE-1)

You may not qualify if:

  • Patients who were diagnosed with pancreatic cancer within 2 years after being diagnosed with chronic pancreatitis (CP)
  • patients with groove pancreatitis,
  • patients with autoimmune pancreatitis.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Changhai Hospital

Shanghai, Shanghai Municipality, 200433, China

Location

Related Publications (2)

  • Thierens N, Verdonk RC, Lohr JM, van Santvoort HC, Bouwense SA, van Hooft JE. Chronic pancreatitis. Lancet. 2025 Dec 21;404(10471):2605-2618. doi: 10.1016/S0140-6736(24)02187-1. Epub 2024 Dec 5.

    PMID: 39647500BACKGROUND
  • Hao L, Wang T, He L, Bi YW, Zhang D, Zeng XP, Xin L, Pan J, Wang D, Ji JT, Du TT, Lin JH, Wang LS, Zou WB, Chen H, Xie T, Guo HL, Li BR, Liao Z, Xu ZL, Li ZS, Hu LH. Risk factor for steatorrhea in pediatric chronic pancreatitis patients. BMC Gastroenterol. 2018 Dec 5;18(1):182. doi: 10.1186/s12876-018-0902-z.

    PMID: 30518343BACKGROUND

Biospecimen

Retention: SAMPLES WITH DNA

feces, for the detection of FE-1

MeSH Terms

Conditions

Pancreatitis, ChronicExocrine Pancreatic Insufficiency

Condition Hierarchy (Ancestors)

PancreatitisPancreatic DiseasesDigestive System DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Liang-hao Hu, MD

    Changhai Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
1 Week
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
professor

Study Record Dates

First Submitted

April 7, 2025

First Posted

April 27, 2025

Study Start

June 1, 2022

Primary Completion

September 30, 2024

Study Completion

October 10, 2024

Last Updated

April 27, 2025

Record last verified: 2025-04

Data Sharing

IPD Sharing
Will not share

Locations